Storia in 2 fonti

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results - Jazz Pharmaceutica

Jazz Pharmaceuticals (JAZZ) reported Q2 sales above estimates and raised its FY26 sales guidance. Analysts have mixed opinions, with some raising price targets. Consider buying JAZZ stock.

Raccontata da

morningstar.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 g fa

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results - Jazz Pharmaceutica

Jazz beat sales at $1.208B (vs $1.115B consensus) and raised FY2026 guidance to $4.600-4.750B, despite EPS miss. All three analysts upgraded price targets, reflecting confidence in pharma IT momentum—a bellwether for enterprise software spending.

originale

morningstar.com2 g fa

Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

Jazz Pharma Q2: $1.2B revenues (+16% YoY), 2026 guidance $4.60–$4.75B on Xywav/Epidiolex strength; Ziihera awaiting August 25 FDA approval. Strong specialty pharma momentum in oncology signals sustained biotech investor confidence and M&A consolidation.

Timeline cronologica

lunedì 3 agosto 2026·morningstar.com
Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
martedì 4 agosto 2026·benzinga.com
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results - Jazz Pharmaceutica
Jazz Pharmaceuticals (JAZZ) reported Q2 sales above estimates and raised its FY26 sales guidance. Analysts have mixed opinions, with some raising price targets. Consider buying…